Business Context and Reporting Period
Company: CollPlant Biotechnologies Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: February 2026 (Specifically covering events on February 4, 2026, with expected closing on February 6, 2026)
Context: The filing announces a registered direct offering of ordinary shares and a concurrent private placement of warrants to institutional investors.
Key Financial Metrics and Transaction Details
- Offering Size: 1,600,000 ordinary shares.
- Share Price: $1.25 per share.
- Gross Proceeds: Approximately $2.0 million (excluding future warrant exercises).
- Warrants Issued:
- Series A: 1,600,000 warrants, exercise price $1.25, 5-year term.
- Series B: 1,600,000 warrants, exercise price $1.25, 18-month term.
- Placement Agent Fees:
- 7.0% of gross proceeds from share sales.
- 1.0% management fee on gross proceeds.
- $35,000 non-accountable expense allowance and $15,950 clearing fees.
- Placement Agent Warrants: 96,000 shares (6.0% of offering), exercise price $1.5625, 5-year term.
- Use of Proceeds: General corporate purposes, including working capital and funding research and development programs.
Note: The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the company's operations.
Material Changes and Restrictions
- Capital Structure Change: The issuance of 1,600,000 new shares and associated warrants represents a dilution event for existing shareholders.
- Lock-Up Period: The Company is restricted from issuing or announcing the issuance of ordinary shares or equivalents for 30 days following the closing.
- Variable Rate Transaction Restriction: The Company cannot enter into a "variable rate transaction" for one year following the closing.
- Ownership Cap: Warrant holders cannot exercise if it would result in beneficial ownership exceeding 4.99% (or 9.99% at election) of outstanding shares.
Outlook, Risks, and Contingencies
- Closing Contingency: The offering is expected to close on or about February 6, 2026, subject to customary closing conditions. Failure to satisfy these conditions may prevent the closing.
- Registration Requirements: The Company must file a registration statement for the resale of warrant shares within 20 days and have it declared effective within 60 days of the Purchase Agreement date.
- Forward-Looking Statements: The filing includes standard disclaimers that future events, including the use of proceeds and closing, are not guaranteed.
- Liquidity Risk: While the offering aims to provide working capital, the filing does not disclose current cash balances or liquidity positions.
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $2.0 million gross proceeds receipt.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination rights.
- Monitor the filing and effectiveness of the registration statement for the warrant shares (required within 60 days).
- Assess the impact of the 1,600,000 new shares and potential warrant exercises on existing shareholder dilution.
- Confirm the company's current cash position and runway, as this filing does not provide operational financial statements.